دورية أكاديمية
Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status.
| العنوان: | Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status. |
|---|---|
| المؤلفون: | Olafsdottir EJ; Icelandic Cancer Registry, Icelandic Cancer Society, Reykjavik, Iceland., Borg A; Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden., Jensen MB; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Gerdes AM; Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Johansson ALV; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Barkardottir RB; Laboratory of Cell Biology, Department of Pathology, Landspitali University Hospital, Reykjavik, Iceland.; Faculty of Medicine, BMC, Laeknagardur, University of Iceland, Reykjavik, Iceland., Johannsson OT; Department of Oncology, Landspitali University Hospital, Reykjavik, Iceland., Ejlertsen B; Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Sønderstrup IMH; Department of Surgical Pathology, Zealand University Hospital, Roskilde, Denmark., Hovig E; Department of Tumor Biology, Institute for Cancer Research, Radium Hospital, Oslo University Hospital, Oslo, Norway., Lænkholm AV; Department of Surgical Pathology, Zealand University Hospital, Slagelse, Denmark., Hansen TVO; Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Olafsdottir GH; Icelandic Cancer Registry, Icelandic Cancer Society, Reykjavik, Iceland., Rossing M; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Jonasson JG; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.; Department of Pathology, Landspitali University Hospital, Reykjavik, Iceland., Sigurdsson S; Cancer Research Laboratory, BMC, School of Health Sciences, University of Iceland, Reykjavik, Iceland., Loman N; Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden., Nilsson MP; Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden., Narod SA; Womens' College Research Institute, University of Toronto, Toronto, ON, Canada., Tryggvadottir L; Icelandic Cancer Registry, Icelandic Cancer Society, Reykjavik, Iceland. laufeyt@krabb.is.; Faculty of Medicine, BMC, Laeknagardur, University of Iceland, Reykjavik, Iceland. laufeyt@krabb.is. |
| المصدر: | British journal of cancer [Br J Cancer] 2020 Nov; Vol. 123 (11), pp. 1608-1615. Date of Electronic Publication: 2020 Sep 17. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK Original Publication: London, Lewis. |
| مواضيع طبية MeSH: | BRCA2 Protein/*genetics , Breast Neoplasms/*genetics , Breast Neoplasms/*metabolism , Receptors, Estrogen/*metabolism, Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/mortality ; Female ; Genetic Predisposition to Disease ; Heterozygote ; Humans ; Middle Aged ; Mutation ; Scandinavian and Nordic Countries |
| مستخلص: | Background: The natural history of breast cancer among BRCA2 carriers has not been clearly established. In a previous study from Iceland, positive ER status was a negative prognostic factor. We sought to identify factors that predicted survival after invasive breast cancer in an expanded cohort of BRCA2 carriers. Methods: We studied 608 women with invasive breast cancer and a pathogenic BRCA2 mutation (variant) from four Nordic countries. Information on prognostic factors and treatment was retrieved from health records and by analysis of archived tissue specimens. Hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression. Results: About 77% of cancers were ER-positive, with the highest proportion (83%) in patients under 40 years. ER-positive breast cancers were more likely to be node-positive (59%) than ER-negative cancers (34%) (P < 0.001). The survival analysis included 584 patients. Positive ER status was protective in the first 5 years from diagnosis (multivariate HR = 0.49; 95% CI 0.26-0.93, P = 0.03); thereafter, the effect was adverse (HR = 1.91; 95% CI 1.07-3.39, P = 0.03). The adverse effect of positive ER status was limited to women who did not undergo endocrine treatment (HR = 2.36; 95% CI 1.26-4.44, P = 0.01) and patients with intact ovaries (HR = 1.99; 95% CI 1.11-3.59, P = 0.02). Conclusions: The adverse effect of a positive ER status in BRCA2 carriers with breast cancer may be contingent on exposure to ovarian hormones. |
| References: | Jonasson, J. G., Stefansson, O. A., Johannsson, O. T., Sigurdsson, H., Agnarsson, B. A., Olafsdottir, G. H. et al. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. Br. J. Cancer 115, 776–783 (2016). (PMID: 10.1038/bjc.2016.249) IMH, Soenderstrup, Laenkholm, A. V., Jensen, M. B., Eriksen, J. O., Gerdes, A. M., TVO, Hansen et al. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG. Acta Oncol. 57, 95–101 (2018). (PMID: 10.1080/0284186X.2017.1398415) Evans, D. G., Harkness, E. F., Howell, A., Wilson, M., Hurley, E., Holmen, M. M. et al. Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality. Hered. Cancer Clin. Pract. 14, 8–15 (2016). (PMID: 10.1186/s13053-016-0048-3) Nilsson, M. P., Hartman, L., Idvall, I., Kristoffersson, U., Johannsson, O. T. & Loman, N. Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status. Breast Cancer Res. Treat. 144, 133–142 (2014). (PMID: 10.1007/s10549-014-2842-9) Nilsson, M. P., Hartman, L., Kristoffersson, U., Johannsson, O. T., Borg, A., Henriksson, K. et al. High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast Cancer Res. Treat. 147, 571–578 (2014). (PMID: 10.1007/s10549-014-3115-3) Winter, C., Nilsson, M. P., Olsson, E., George, A. M., Chen, Y., Kvist, A. et al. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann. Oncol. 27, 1532–1538 (2016). (PMID: 10.1093/annonc/mdw209) Nilsson, M. P., Törngren, T., Henriksson, K., Kristoffersson, U., Kvist, A., Silfverberg, B. et al. BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer. Breast Cancer Res. Treat. 168, 17–126 (2018). (PMID: 10.1007/s10549-017-4584-y) Rebbeck, T. R., Mitra, N., Wan, F., Sinilnikova, O. M., Healey, S., McGuffog, L. et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313, 1347–1361 (2015). (PMID: 10.1001/jama.2014.5985) Royston P. “PTREND: Stata module for trend analysis for proportions”, Statistical Software Components S426101, (Boston College Department of Economics, 2014). Coviello, V. & Boggess, M. Cumulative incidence estimation in the presence of competing risks. Stata J. 4, 103–112 (2004). (PMID: 10.1177/1536867X0400400201) Lambert, P. C. & Royston, P. Further development of flexible parametric models for survival analysis. Stata J. 9, 265–290 (2009). (PMID: 10.1177/1536867X0900900206) BAM, Heemskerk-Gerritsen., Seynaeve, C., van Asperen, C. J., MGEM, Ausems., Collée, J. M. & van Doorn, H. C. et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J. Natl Cancer Inst. 107, 1–9 (2015). Bentzon, N., Düring, M., Rasmussen, B. B., Mouridsen, H. & Kroman, N. Prognostic effect of estrogen receptor status across age in primary breast cancer. Int. J. Cancer 122, 1089–1094 (2008). (PMID: 10.1002/ijc.22892) Foulkes, W. D., Metcalfe, K., Sun, P., Hanna, W. M., Lynch, H. T., Ghadirian, P. et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin. Cancer Res. 10, 2029–2034 (2004). (PMID: 10.1158/1078-0432.CCR-03-1061) Hahnen, E., Lederer, B., Hauke, J., Loibl, S., Kröber, S., Schneeweiss, A. et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncol. 3, 1378–1385 (2017). (PMID: 10.1001/jamaoncol.2017.1007) Azzato, E. M., Greenberg, D., Shah, M., Blows, F., Driver, K. E., Caporaso, N. E. et al. Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? BJC 100, 1806–1811 (2009). (PMID: 10.1038/sj.bjc.6605062) Schmidt M. K., van den Broek A. J., Tollenaar R. A., Smit VTH, Westenend P. J., Brinkhuis M., et al. Breast cancer survival of BRCA1/BRCA2 mutation carriers in a hospital-based cohort of young women. J. Natl Cancer Inst. 109, 1–10 (2017). Copson, E. R., Maishman, T. C., Tapper, W. J., Cutress, R. I., Greville-Heygate, S., Altman, D. G. et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 19, 169–180 (2018). (PMID: 10.1016/S1470-2045(17)30891-4) Metcalfe, K., Lynch, H. T., Foulkes, W. D., Tung, N., Olopade, O. I., Eisen, A. et al. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. BJC 120, 398–403 (2019). (PMID: 10.1038/s41416-019-0376-y) Vocka, M., Zimovjanova, M., Bielcikova, Z., Tesarova, P., Petruzelka, L., Mateju, M. et al. Estrogen receptor status oppositely modifies breast cancer prognosis in BRCA1/BRCA2 mutation carriers versus non-carriers. Cancers (Basel). 11, 738 (2019). (PMID: 10.3390/cancers11060738) Liu, Y.-R., Jiang, Y.-Z., Yu, K.-D. & Shao, Z.-M. Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis. Ann. Surg. Oncol. 22, 1102–1110 (2015). (PMID: 10.1245/s10434-014-4108-5) Sopik, V., Sun, P. & Narod, S. A. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients. Breast Cancer Res. Treat. 165, 391–402 (2017). (PMID: 10.1007/s10549-017-4333-2) Johansson, A. L. V., Trewin, C. B., Hjerkind, K. V., Ellingjord-Dale, M., Johannesen, T. B. & Ursin, G. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort. Int. J. Cancer 144, 1251–1261 (2019). (PMID: 10.1002/ijc.31950) Tryggvadottir, L., Olafsdottir, E. J., Olafsdottir, G. H., Sigurdsson, H., Johannsson, O. T., Bjorgvinsson, E. et al. Tumour diploidy and survival in breast cancer patients with BRCA2 mutations. Breast Cancer Res. Treat. 140, 375–384 (2013). (PMID: 10.1007/s10549-013-2637-4) Rakha, E. A., Reis-Filho, J. S., Baehner, F., Dabbs, D. J., Decker, T., Eusebi, V. et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 12, 207–218 (2010). (PMID: 10.1186/bcr2607) Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S. Smeds, J. et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst. 98, 262–272 (2006). (PMID: 10.1093/jnci/djj052) Maxwell, K. N., Wubbenhorst, B., Wenz, B. M., De Sloover, D., Pluta, J., Emery, L. et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat. Commun. 8, 319 (2017). (PMID: 10.1038/s41467-017-00388-9) |
| المشرفين على المادة: | 0 (BRCA2 Protein) 0 (BRCA2 protein, human) 0 (Receptors, Estrogen) |
| تواريخ الأحداث: | Date Created: 20200917 Date Completed: 20210318 Latest Revision: 20210918 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC7686356 |
| DOI: | 10.1038/s41416-020-01056-4 |
| PMID: | 32939053 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1532-1827 |
|---|---|
| DOI: | 10.1038/s41416-020-01056-4 |